Ahu PAKETÇİ, Sezer ACAR, Korcan DEMİR, Ayhan ABACI, Ece BÖBER

Hemanjiyom İçin Propranolol Tedavisi Alan Bir İnfantta Gelişen Semptomatik Hipoglisemi: Olgu Raporu ve Önlemler

İnfantil hemanjiyom erken çocukluk döneminde sık görülen benign vasküler bir tümördür. Tipik olarak küçük bir lezyon olarak başlar, ilk dokuz ayda hızla büyür ve yıllar içinde geriler. İnfantil hemanjiyom vakalarının yaklaşık %20’si kanama, ülserasyon ve obstrüksiyon nedeniyle tedavi gerektirir. Bir beta bloker olan propranolol günümüzde infantil hemanjiyom tedavisinde ilk seçenektir. Büyümeyi engellemek için olabildiğince erken başlanması, lezyonun tekrar etme riskini azaltmak için de en az bir yıl süreyle kullanılması gerekmektedir. Propranalol, etkin ve güvenilir bir tedavi olmakla birlikte, hipoglisemi ve buna bağlı konvülziyon, bradikardi, hipotansiyon, atriyoventriküler blok ve bronkospazm gibi ciddi yan etkilere neden olabilir. Bu makalede, hemanjiyoma yönelik propranolol tedavisi altında iken ciddi hipoglisemi gelişen 18 aylık (bir kız) olgunun klinik özellikleri sunulmuştur.

An Infant Who Developed Symptomatic Hypoglycemia During Propranolol Treatment for Hemangioma: Case Report and Precautions

Infantile hemangioma is common benign vascular tumor in early childhood. It typically appears as a small lesion, grows rapidly during the first nine months of life, and resolves over years. Approximately 20% of cases with infantile hemangioma require treatment due to bleeding, ulceration, and obstruction. Propranolol, a beta-blocker, is the first-choice treatment for infantile hemangioma. It must be started as soon as possible to prevent growth and must be used for at least one year to reduce the risk of recurrence of the lesion. Propranolol is an effective and safe treatment, however, it may cause severe side effects such as hypoglycemia and associated convulsion, bradycardia, hypotension, atrioventricular block, and bronchospasm. In this report, we present the clinical features of an 18-month-old female infant with severe hypoglycemia under propranolol therapy for hemangioma.

PDF

___

Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics 2016; 138(4).
Janmohamed SR, Madern GC, de Laat PC, Oranje AP. Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I). European journal of pediatrics 2015; 174(1): 97-103.
Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. The New England journal of medicine 2015; 372(8): 735-746.
MacIsaac ZM, Nayar HS, Gehris R, Mehta D, Geisler S, Grunwaldt LJ. Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. The Journal of craniofacial surgery 2016; 27(1): 159-162.
de Graaf M, Breur JM, Raphael MF, Vos M, Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. Journal of the American Academy of Dermatology 2011; 65(2): 320-327.
Nguyen HP, Pickrell BB, Wright TS. Beta-blockers as therapy for infantile hemangiomas. Seminars in plastic surgery 2014; 28(2): 87-90.
Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatric dermatology 2013; 30(2): 182-191.
Taylor RH. Infantile Periocular Haemangioma: Optimising the Therapeutic Response. Paediatric drugs 2016; 18(3): 157-160.
Wedgeworth E, Glover M, Irvine AD, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. The British journal of dermatology 2016; 174(3): 594-601.
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131(1): 128-140.